Survival of cervix cancer patients in Kampala, Uganda: 1995–1997 by Wabinga, H et al.
Short Communication
Survival of cervix cancer patients in Kampala, Uganda: 1995–1997
H Wabinga*,1, AV Ramanakumar
2, C Banura
3, A Luwaga
4, S Nambooze
1 and DM Parkin
2
1Kampala Cancer Registry, Department of Pathology, Makerere University Medical School, Kampala, Uganda;
2International Agency for Research on
Cancer, 69372 Lyon Cedex 08, France;
3Ministry of Health, Kampala, Uganda;
4Department of Radiotherapy, Makerere University Medical School,
Kampala, Uganda
The survival experience of 261 patients with cancer of the cervix registered by the Kampala population-based cancer registry,
Uganda, in 1995–1997, is described. Vital status of the subjects was established by active methods including a search of hospital
records and house visits. Of the 261 cases, 82 (31.4%) were dead and 105 (40.2%) were alive at the closing date of 31 December
1999; the remaining 74 cases (28.4%) were lost during the follow-up period. Overall observed and relative survival at 3 years was
52.4 and 59.9%, respectively. Of these cases, one-quarter (63) had been treated in the radiotherapy department. These cases had
better survival (82.6%) than nontreated patients (78.5%) after 1 year of follow-up, but there was no difference at 3 years. HIV status
was not significantly related to prognosis. Stage is an important determinant of survival: cases with distant metastasis had a risk of
death some three times that of patients with localised disease. Early detection and prompt treatment should improve overall survival
from cervix cancer, in the African context.
British Journal of Cancer (2003) 89, 65–69. doi:10.1038/sj.bjc.6601034 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: cervix; Africa; survival; radiotherapy; treatment
                                        
Cancer of the cervix uteri is the second most common cancer
among women worldwide, with a particularly high incidence in
sub-Saharan Africa, where there were an estimated 57000 cases in
2000, comprising 22% of all cancers in women (Parkin et al, 2003).
The stage at presentation of tumours in African women is generally
very advanced (Schonland and Bradshaw, 1969; Rogo et al, 1990;
Lomalisa et al, 2000). Facilities for the adequate clinical manage-
ment of those cases that do present at a stage where therapy might
be successful are often very inadequate; for example, radiotherapy
is available in only 16 of 50 counties in sub-Saharan Africa, and the
provision of equipment quite insufficient to deal with the numbers
of cancer cases requiring therapy (Levin et al, 1997). Nothing is
known of the outcome (survival) of women diagnosed with cancer
of the cervix in these circumstances. Only a few data from highly
selected clinical series have been published (Walker et al, 1985),
and there has been no attempt to estimate population-based
survival for any population on the African continent.
In this paper, we report on a study of survival of women with
cancer of the cervix diagnosed among residents of Kyadondo
County, Uganda, during the period 1995–1997. Kyadondo County
includes the capital city of Uganda, Kampala, as well as
surrounding peri-urban and rural areas, with a total surface area
of 1914km
2 and a population (1997) of 1.2 million. Cancer of the
cervix is the most important tumour among women in Uganda,
with an age-standardised incidence of 41.7 per 10
5 in Kyadondo
county in 1993–1997 (Parkin et al, 2002). We also compare the
survival pattern of patients that received radiotherapy treatment
and those that did not.
SUBJECTS AND METHODS
The Kampala Cancer Registry, located in the Department of
Pathology at Makerere Medical School, registers all new cancer
cases occurring among residents of Kyadondo County. Case
finding is by active search for cancers diagnosed in three pathology
laboratories, or in six hospitals in the area, or followed up by the
Uganda Hospice. Death certificates are rarely completed for deaths
occurring outside hospital, and are therefore not used as a source
of information. The registry methods and results have been
described previously (Wabinga et al, 1993, 2000).
All incident cases of cervix cancer registered during 1993–1997
in the Kampala Cancer Registry were selected for the study of
survival. Information abstracted included names, age, residential
address, tribe, HIV status, admission date, basis of diagnosis, date
of last contact, and status at last contact. HIV status was available
for a considerable number of cases in this period because of a
separate study of the association between HIV infection and cancer
(Newton et al, 2001) being conducted in the Kampala hospitals.
Follow-up of these subjects was conducted during 2001–2002 to
establish their vital status at the closing date of the study, 31
December 1999. For those cases not known to have died, the first
stage in the follow-up required tracing the patients’ clinical records
in the local hospitals, to retrieve available information on patient
status, to complete any that had been missing from the registry
record, and to abstract any recorded information on stage of
disease at diagnosis (as TNM or FIGO stage). The case file was also
linked with the computerised database of the Uganda Hospice
using the RECLINK software, to identify those cases that had been
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yreferred there for management. (RECLINK is a record linkage
software developed at unit of Descriptive Epidemiology, Interna-
tional Agency for Research on Cancer, Lyon. The software
performs probabilistic linkage between records from different
sources using selected personal identifiers (names, date of birth,
sex, address, tribe). The hospice provides outreach palliative care
(including counselling, basic chemotherapy, or pain relief) for
cancer patients, and follows up all referred cases to them,
including those that did not receive any treatment after the initial
consultation. The cases for which information on vital status at the
closing date was not available from these sources were followed up
by home visits. The process is difficult, since formal addresses do
not exist in Uganda. The place of residence is recorded simply as
the name of the locality; street names and house numbers are not
used. In the more rural areas, the local chiefs or leaders were asked
for information on the exact place where the patient lived. The
offices of lowest level of local government (Local Council II)
maintain a list of people living in the area, based on the register of
voters. Registration is needed in order to vote, but is not
compulsory. If these procedures failed to locate an individual,
the project staff made enquiries of other local residents whether
they knew about the person in question. In the urban areas, local
councillors were usually asked, but since many urban area
residents are tenants of rented property, not homeowners, this
method was less successful than in rural areas.
Details of all cervix cancer cases referred to the Department of
Radiotherapy in the period 1993–1997 were recorded in a
computer file, which included patient details, stage of disease, as
well as information on the type of therapy given and follow-up.
This radiotherapy file was then matched with the file of registered
cervix cancer cases from Kyadondo County using RECLINK. In
fact, since the Department of Radiotherapy was closed during 1993
and 1994, the final analysis of results of the study comprised only
those cases diagnosed during the 3-year period, 1995–1997.
Data entry used the Epi-infot software and the files were
exported to STATAt for analysis. Cumulative observed probabil-
ities were calculated using the Kaplan–Meier method. To calculate
observed survival, death from any cause was taken as failure, and
the subjects who were lost to follow-up prior to the closing date, and
those known to be alive on the closing date were censored on those
dates. Observed survival was also calculated using two other
assumptions: that all cases lost to follow-up had died on the date of
lost follow-up (minimum survival), or that such patients remained
alive until the closing date of the study (maximum survival).
Cumulative relative survival probabilities were calculated using
Hakulinen’s method (Hakulinen and Abeywickrama, 1985). The
probability of death, by age, was taken from the Uganda life tables
for the year 2000 published by the World Health Organization
(WHO, 2000). The log-rank test was used in a univariate analysis to
identify potentially important prognostic variables. The variables
that showed statistical significance on univariate analysis were
introduced stepwise into a Cox regression model to identify the
independent predictors of survival. Age standardisation of the
relative survival was carried out by the direct method, using six age
groups (o35, 35–44, 45–54, 55–64, 65–74, 75þ) and the standard
patient population provided by Sankaranarayanan et al (1998).
RESULTS
A total of 261 cases of cervix cancer were recorded among
Kyadondo residents for the 3-year period 1995–1997. Of these
Table 1 Distribution of cervix cancer cases in Kampala, Uganda, 1995–1997
Radiotherapy (63) No radiotherapy (198) All cases (261)
No. (%) No. (%) No. (%)
Age
o35 (years) 17 (26.9) 46 (23.2) 63 (24.1)
35–44 15 (23.8) 64 (32.3) 79 (30.3)
45–54 20 (31.8) 42 (21.2) 62 (23.8)
55–64 5 (7.9) 22 (11.1) 27 (10.3)
65+ 6 (9.6) 24 (12.2) 30 (11.5)
Mean age 44.0 45.5 45.1
Stage
Stage I 17 (27.4) 21 (10.6) 38 (27.9)
Stage II 35 (56.4) 22 (10.6) 57 (41.9)
Stage III 9 (14.5) 19 (12.6) 28 (20.6)
Stage IV 1 (1.6) 12 (6.6) 13 (9.6)
Missing 1 (1.6) 124 (62.6) 125 (47.9)
Basis of diagnosis
Nonhistological 14 (22.2) 79 (39.9) 92 (35.2)
Histology 49 (77.8) 119 (60.1) 169 (64.8)
Tribe
Ganda 41 (65.1) 121 (61.1) 162 (62.1)
Others 22 (34.9) 76 (38.4) 98 (37.5)
Missing 0 1 (0.5) 1 (0.4)
Vital status
Dead 17 (27.0) 65 (32.8) 82 (31.4)
Alive 34 (54.0) 71 (35.9) 105 (40.2)
Lost FU 12 (19.0) 62 (31.3) 74 (28.4)
HIV infection
Yes 21 (33.3) 48 (24.2) 69 (26.4)
No 30 (47.6) 64 (32.3) 94 (36.0)
Missing 12 (19.0) 86 (43.4) 98 (37.6)
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ycases, 63 (24%) had been referred to the Department of Radio-
therapy. Table 1 shows the distribution of cases by age, stage, basis
of diagnosis, tribe, HIV status, and vital status on the closing date
of the study. Of the 261 eligible cases, 82 (31.4%) were known to
have died, 105 (40.2%) were known to have been alive on the
closing date, and 74 (28.3%) had been lost to follow-up. The cases
lost to follow-up did not differ from those successfully traced in
terms of age (mean ages were 45.6 in those lost and 44.1 in those
traced, Po0.23), tribe, stage, or HIV status. Only 63 cases
(24.1%) had been treated by radiotherapy. The mean age of these
cases was 44.0, compared with 45.5 for those not receiving
treatment by radiotherapy (t¼1.81 and Po0.04). Stage was clearly
important in determining treatment; only 24% of cases in stages III
and IV had received radiotherapy, compared with 61% of cases in
stage II (who might be expected to profit the most), and 45% in
stage I (who would be treated by surgery as the method of choice).
The diagnosis in 78% of the radiotherapy cases had been
confirmed histologically, while only 60% had been histologically
confirmed in the nontreatment group. HIV status was known for
163 (62.4%) of cervix cancer patients; 69 (42.3% of those with
known status) were HIV positive. HIV status did not seem to have
determined the use, or otherwise, of radiotherapy, although the
percentage of cases in which HIV status was known was much
higher in the radiotherapy cases (81%) than in those not referred
for treatment (56.5%).
With respect to the radiotherapy treatment, only one in four
patients (16 out of 63) had received both external beam and
intracavity radiation. Almost half of the patients (30 out of 63)
received treatment by external beam alone, and nine cases by
intracavity radiation alone.
Observed and relative survival is shown in Figure 1. Overall
observed and relative survival at 3 years was 52.4 and 59.9%,
respectively. Cases treated by radiotherapy had a significantly
better survival in the first year of follow-up (82%) compared with
nontreated patients (78.5%), but this advantage had disappeared 2
years post diagnosis. Information on clinical staging was available
for 52.1% of cases. Survival declined steadily with advancing stage
of disease at diagnosis. Among the cases for which HIV status was
known, there was no difference in survival at 1 (P¼0.09), 3
(P¼0.23), or 4 years (P¼0.72) post diagnosis.
Independent predictors of survival using the Cox proportionate
hazards model are presented in Table 2. Stage is the most
important determinant of survival: cases with distant metastasis
(stage IV) had a risk of death some three times that of patients with
localised disease. The somewhat increased risk of death with
advancing age seen in the univariate analysis is not present when
the other variables (especially stage) are included in the model.
Tribe, HIV status, and treatment by radiotherapy were not related
to prognosis.
The possible effects of the loss to follow-up of 74 (28.4%) of
cases were examined by calculating a maximum survival (assum-
ing that all were alive at the closing date) and a minimum survival
(assuming that all such patients had died at the date of follow-up).
Figure 2 shows the observed survival, calculated by the actuarial
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Figure 1 Observed and relative survival from cervix cancer in Kampala,
Uganda, 1995–1997
Table 2 Independent predictors of death in 261 cases of cancer of
cervix uteri, Kampala, Uganda, 1995–1997
Odds ratios and 95% confidence intervals
Predictor Univariate Multivariate
Age (years)
o35 1.0 1.0
35–44 1.5 (0.9–2.4) 0.9 (0.4–1.9)
45–54 1.6 (1.0–2.6) 1.0 (0.5–2.2)
55–64 2.0 (1.1–3.6) 2.3 (0.8–6.3)
65+ 2.2 (1.2–4.0) 1.7 (0.6–5.3)
Stage
Stage I 1.0 1.0
Stage II 0.8 (0.4–1.7) 0.9 (0.4–2.0)
Stage III 1.5 (0.6–3.4) 1.8 (0.7–4.4)
Stage IV 3.1 (1.3–7.5) 3.1 (1.1–8.8)
Unknown 0.4 (0.2–0.8) 0.3 (0.1–0.8)
Treatment
Radio therapy 1.0 1.0
Not treated 0.9 (0.5–1.6) 1.0 (0.5–2.1)
Tribe
Ganda 1.0 1.0
Other 1.2 (0.8–1.9) 1.3 (0.7–2.3)
HIV infection
Positive 1.0 1.0
Negative 0.9 (0.6–1.5) 0.7 (0.4–1.2)
0
20
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Figure 2 Observed survival (with 95% CI) and estimated maximum and
minimum values. Cervix cancer cases, Kampala, Uganda 1995–1997
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years, the observed survival was 54.2%, with a minimum estimate
of 36.6% and a maximum of 64.4%.
DISCUSSION
The patients represented all of the cases diagnosed in the
population of Kyadondo County, Uganda, in 1995–1997. The
Kampala Cancer Registry was founded in 1954, in the Department
of Pathology of Makerere University Medical School. The aim was
to obtain information on cancer occurrence in the population of
Kyadondo County in which the capital city of Kampala is situated.
The registry functioned continuously until 1971, when, because of
the unstable political situation, full population coverage became
impossible. The registry was restarted (in 1989) and has functioned
continuously since. When it began, the registry relied upon
request/result forms of the Department of Pathology, which had
been redesigned specifically to permit registration of cancers. In
addition to data collected in this way, tumour registrars have been
employed to search for cancer cases admitted to, or treated in, all
of the hospitals in Kampala (and, in recent years, the Uganda
Hospice) and, for individuals resident in Kyadondo County, to
extract somewhat more extensive information onto special
notification forms. The registry file has been maintained on
computer since 1989.
Incidence rates, for the population of Kyadondo County, have
been published for 1989–1991 (Wabinga et al, 1993) and 1993–
1997 (in Parkin et al, 2002). A complete review of the data set, for
four time periods (1960–1966, 1967–1971, 1991–1994, 1995–
1997), has been published by Wabinga et al (2000). The incidence
rate of cervix cancer in women is high, and the rates have
increased markedly between the 1950s and 1960s, and the 1990s.
This increase is unlikely to be related to the epidemic of AIDS. It is
possible that the social disruption of the Amin dictatorship and the
following civil wars (1972–1986) favoured the spread of HPV, like
other sexually transmitted diseases; HPV was found to be present
in the great majority of cervix cancers in Uganda, with HPV type
16 in 53% (Bosch et al, 1995).
The results show that survival at 3 years (52.4%) is fair, and
certainly not as poor as is often assumed for cervix cancer in Africa
(Sherris et al, 2002). The result may be compared with 1 and 3
years age-standardised relative survival (0–74 years) in nine other
populations (Table 3).
These are the first population-based survival data from Africa.
Cancer registration that involves identification of all new cases
arising in a defined population is a difficult proposition in Africa
(Parkin et al, 2003), but the follow-up of all registered cases for
periods of several years adds a further degree of complexity. In
Kampala, tracing patients at home proved to be quite difficult,
since addresses consist simply of a local area; street names and
numbers do not exist. In addition, most urban residents retain a
connection with their ‘home’ village, to which they may well
return, to be with relatives at the time of death. Tracing more than
70% of patients was therefore a reasonable achievement by the
project staff. Furthermore, the patients who were not traced did
not seem to be a biased subgroup, at least in terms of demographic
characteristics, or HIV status. They may, however, have been more
(or less) likely to die than the patients who were successfully
traced. The maximum and minimum survival estimates provide a
range for the true value.
As in other studies from Africa, the stage of disease at diagnosis
is relatively advanced, although the percentage of cases in stage 1
(27.9%) is higher than in previously reported series from Africa; it
was only 7% among cases treated by radiotherapy in Nairobi,
Kenya, in 1974–1979 (Rogo et al, 1990) and 8.4% in cases admitted
to Johannesburg Hospital in 1997–1998 (Lomalisa et al, 2000). The
higher percentage of cases in stage I probably reflects both the
general level of health awareness in the population and easy access
to medical facilities in Kyadondo county. As has been noted in
many previous studies (Sankaranarayanan et al, 1998), stage is an
important determinant of survival from cervix cancer, and the only
significant influence on outcome in the present study. The rather
low observed survival may also relate to competing causes of death
in this population. Uganda was one of the first countries affected
by the epidemic of HIV/AIDS, although by the time of this study
(1995–1997) prevalence of infection had more than halved since
the maximum in the early 1990s, the peak age group for diagnosis
of AIDS in women in Uganda is 25–29, and two-thirds of AIDS
cases occur under the age of 35 years (Ministry of Health, 2002),
while this age group had a lower case fatality from cervix cancer
than older women (Table 2). HIV status was known for almost
two-thirds of cases, and, although HIV-positive subjects had a
rather higher risk of dying than those who were negative, the
difference was not significant.
It is perhaps surprising that less than a quarter of the cases had
received any radiotherapy; the stage of disease was clearly
important in selecting the cases most likely to benefit. HIV
positivity is not considered to be a contraindication. The outcome
in cases treated by radiotherapy was no better than for those who
were not (except possibly in the first year of follow-up).
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Table 3 One-year and 3-year age-standardised relative survival (ASRS)
from cancer of the cervix in selected populations of women aged 0–74
years
Country/population Period
ASRS
(1 year)
ASRS
(3 years)
Uganda, Kampala 1995–1997 81.4 49.0
Zimbabwe, Harare
1 1995–1997 66.1 44.9
India, Mumbai
1 1992–1994 77.4 57.5
China, Qidong
1 1987–1991 60.1 45.0
Thailand, Khon Kaen
1 1993–1997 58.5 41.3
UK, Northern Ireland
2 1993–1996 83.0 70.0
Europe
3 1985–1989 92.1 85.0
United States, SEER registries
4 1995 89.7
5 78.1
5
Canada, Ontario
6 1971–1996 89.3 78.9
Australia, New South Wales
2 1980–1995 89.9 70.9
1Unpublished results from the registries (see Acknowledgements).
2N Ireland Cancer
Registry (2001).
3Berrino et al (1999).
4Ries et al (2001).
5Relative survival in SEER
population: age-specific data unavailable.
6Marrett et al (1999).
7NSW Cancer
Council (2002).
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